Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix versus goserelin + bicalutamide for neoadjuvant prostate volume reduction before radiotherapy
2008-005232-33Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Nov 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of degarelix, goserelin, bicalutamide in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Started Nov 2008; status: completed.
02
Drugs
degarelixgoserelinbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-005232-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005232-33.